Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (4): 49-55.doi: 10.6040/j.issn.1671-7554.0.2022.1015

• 临床医学 • Previous Articles    

Prognostic value of CCR gene in clear cell renal cell carcinoma based on database

HU Liyong1, ZHONG Hao1,2, FANG Juanjuan3, GUO Wei1, ZHANG Yulu4, FAN Yidong1   

  1. 1. Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Urology, The Third Peoples Hospital of Linyi, Linyi 276023, Shandong, China;
    3. Department of Anesthesiology, Dezhou Hospital, Qilu Hospital, Shandong University, Dezhou 254300, Shandong, China;
    4. Department of Clinical Medicine, Shandong First Medical University, Jinan 250024, Shandong, China
  • Published:2023-04-11

PDF (PC)

334

Abstract: Objective To explore the prognostic value of CC chemokine receptor(CCR)gene family in patients with clear cell renal cell carcinoma(ccRCC)based on database. Methods The gene expression data were downloaded from The Cancer Genome Atlas(TCGA)and analyzed to screen the differentially expressed genes of CCR family in normal tissues and ccRCC tissues. The prognostic model was constructed with COX regression analysis, and relevant functional analysis was carried out. Results Transcriptome data of 539 ccRCC tissues and 72 normal tissues were downloaded from the TCGA database, and 11 differentially expressed CCR genes were screened out. Two CCR genes(CCR3 and CCR10)associated with ccRCC prognosis were obtained, and the prognostic model was constructed. According to the median risk score of the model, the training set samples were divided into high risk group(n=184)and low risk group(n=197). Kaplan-Meier analysis showed that the overall survival rate of low-risk group was significantly higher than that of high-risk group(P<0.001). Conclusion The prognostic model of CCR gene constructed in this study can effectively evaluate the prognosis of ccRCC patients and guide the individualized treatment.

Key words: Clear cell renal cell carcinoma, Chemokine receptor family, Prognostic model, Immunotherapy

CLC Number: 

  • R737.11
[1] Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3: 17009. doi: 10.1038/nrdp.2017.9.
[2] Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney [J]. Cancer Res, 2009, 69(11): 4674-4681.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(1): 7-30.
[4] Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer [J]. Nat Rev Urol, 2010, 7(5): 245-257.
[5] Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions [J]. CA Cancer J Clin, 2017, 67(6): 507-524.
[6] Capitanio U, Montorsi F. Renal cancer [J]. Lancet, 2016, 387(10021): 894-906.
[7] Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity [J]. Annu Rev Immunol, 2014, 32: 659-702. doi: 10.1146/annurev-immunol-032713-120145.
[8] Sokol CL, Luster AD. The chemokine system in innate immunity [J]. Cold Spring Harb Perspect Biol, 2015, 7(5): a016303. doi: 10.1101/cshperspect.a016303.
[9] Allison SJ. Kidney cancer: CCR4: a new target for RCC [J]. Nat Rev Nephrol, 2017, 13(4): 192. doi:10.1038/nrneph.2017.14.
[10] Mollica Poeta V, Massara M, Capucetti A, et al. Chemokines and chemokine receptors: new targets for cancer immunotherapy [J]. Front Immunol, 2019, 10: 379. doi: 10.3389/fimmu.2019.00379.
[11] Lacalle RA, Blanco R, Carmona-Rodríguez L, et al. Chemokine receptor signaling and the hallmarks of cancer [J]. Int Rev Cell Mol Biol, 2017, 331: 181-244. doi: 10.1016/bs.ircmb.2016.09.011.
[12] Korbecki J, Kojder K, Simińska D, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4 [J]. Int J Mol Sci, 2020, 21(21): 8412. doi: 10.3390/ijms21218412.
[13] Sun Z, Qin X, Fang J, et al. Multi-omics analysis of the expression and prognosis for FKBP gene family in renal cancer [J]. Front Oncol, 2021, 11: 697534. doi: 10.3389/fonc.2021.697534.
[14] Bhat AA, Nisar S, Maacha S, et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy [J]. Mol Cancer, 2021, 20(1): 2. doi: 10.1186/s12943-020-01294-3.
[15] Marshall LA, Marubayashi S, Jorapur A, et al. Tumors establish resistance to immunotherapy by regulating T(reg)recruitment via CCR4 [J]. J Immunother Cancer, 2020, 8(2): e000764. doi: 10.1136/jitc-2020-000764.
[16] Kraus S, Kolman T, Yeung A, et al. Chemokine receptor antagonists: role in oncology [J]. Curr Oncol Rep, 2021, 23(11): 131. doi: 10.1007/s11912-021-01117-8.
[17] Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy [J]. Cytokine Growth Factor Rev, 2010, 21(1): 27-39.
[18] Thomas JK, Mir H, Kapur N, et al. CC chemokines are differentially expressed in breast cancer and are associated with disparity in overall survival [J]. Sci Rep, 2019, 9(1): 4014. doi: 10.1038/s41598-019-40514-9.
[19] Cho H, Lim SJ, Won KY, et al. Eosinophils in colorectal neoplasms associated with expression of CCL11 and CCL24 [J]. J Pathol Transl Med, 2016, 50(1): 45-51.
[20] Lorena SC, Oliveira DT, Dorta RG, Landman G, Kowalski LP. Eotaxin expression in oral squamous cell carcinomas with and without tumour associated tissue eosinophilia [J]. Oral Dis, 2003, 9(6): 279-283.
[21] Sharma I, Singh A, Sharma K, et al. Gene expression profiling of chemokines and their receptors in low and high grade astrocytoma [J]. Asian Pac J Cancer Prev, 2017, 18(5): 1307-1313.
[22] Jin L, Liu WR, Tian MX, et al. CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis [J]. Oncotarget, 2017, 8(3): 5135-5148.
[23] Park JY, Kang YW, Choi BY, et al. CCL11 promotes angiogenic activity by activating the PI3K/Akt pathway in HUVECs [J]. J Recept Signal Transduct Res, 2017, 37(4): 416-421.
[24] Pivarcsi A, Müller A, Hippe A, et al. Tumor immune escape by the loss of homeostatic chemokine expression [J]. Proc Natl Acad Sci U S A, 2007, 104(48): 19055-19060.
[25] Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001, 410(6824): 50-56.
[26] Yang XL, Liu KY, Lin FJ, et al. CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis [J]. Oncol Rep, 2017, 38(3): 1393-1401.
[27] Ji L, Qian W, Gui L, et al. Blockade of β-Catenin-Induced CCL28 suppresses gastric cancer progression via inhibition of treg cell infiltration [J]. Cancer Res, 2020, 80(10): 2004-2016.
[28] Roy I, Boyle KA, Vonderhaar EP, et al. Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma [J]. Lab Invest, 2017, 97(3): 302-317.
[29] Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy [J]. Cell, 2017, 168(4): 707-723.
[30] 周莹,张博恒,殷欣,等. 趋化因子CCL28在缺氧诱导肝癌细胞侵袭中的作用[J]. 中华肝脏病杂志, 2013, 21(7): 524-527. ZHOU Ying, ZHANG Boheng, YIN Xin, et al. Role of chemokine CCL28 in hypoxia- induced migration of hepatocellular carcinoma [J]. Chinese Journal of Hepatology, 2013, 21(7): 524-527.
[1] ZHANG Zhenwei, LI Jia, CHEN Keming. IGF2BP2/m6A/ITGA5 signal axis regulates the proliferation and migration of renal clear cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 74-84.
[2] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[3] Huijiang GAO,Yucheng WEI. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[4] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[5] DENG Xiaohui, GUO Ling. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37.
[6] LI Canxuan, CHEN Jie. Expression and activity mechanism of acetyl-CoA acyltransferase 1 in clear cell renal cell carcinoma based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 26-33.
[7] PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.
[8] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[9] Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73.
[10] LUO Xin, HE Bing, NIE Qingsheng, HOU Zhenbo, DONG Jun, LI Yuhua, ZENG Xiangqin, LIU Wei, KONG Demin, CAO Jinfeng. Comparison of the value of mono-exponential mode and diffusion kurtosis imaging mode in grading clear cell renal cell carcinoma using magnetic resonance diffusion-weighted imaging [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 89-95.
[11] WU Depei, CHEN Xiaochen. Current situation and prospect of immunotherapy for lymphoma [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 13-20.
[12] HUANG Xiaojun. Advances of cellular immunotherapy for hematologic malignancies [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 1-5.
[13] WANG Zhao. Advances in the clinical treatment of hemophagocytic lymphohistiocytosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 44-49.
[14] ZHAO Zuohui, LI Cuiling, WANG Daoguang, WANG Fengqin, QU Hongyi, DING Sentai, GONG Jing, LÜ Jiaju, YANG Jinghua. Effect of MnSOD acetylation on the proliferation and apoptosis of clear cell renal cell carcinoma cell line 786-O [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 31-35.
[15] ZHENG Min, ZHANG Lan. Current situation and development trend of CAR-T in anti-tumor research [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 1-6.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd